Table 1 Socio-demographic and clinical characteristics of the study sample (n = 129)
Characteristic | Sample (n = 129) |
|---|---|
Gender (n, %) | |
Male | 115 (89.1) |
Female | 14 (10.9) |
Age (years) | 60.9 ± 8.8 |
Marital status (n, %) | |
Married | 106 (82.2) |
Single/Divorced/Windowed/Separated | 23 (17.8) |
Highest education level (n, %) | |
No formal education | 8 (6.2) |
Primary education | 26 (20.2) |
Secondary education | 60 (46.5) |
Tertiary education and above | 35 (27.1) |
Employment status (n, %) | |
Full-time/Part-time working | 87 (67.4) |
Retired/Not working | 42 (32.6) |
Monthly household income (SGD) | |
≤ 1000 | 23 (17.8) |
1001–3000 | 46 (35.7) |
3001–5000 | 30 (23.3) |
> 5000 | 29 (22.5) |
Type of housing (n, %) | |
Government house/HDB flat | 122 (94.6) |
Private house | 7 (5.4) |
Clinical characteristics | |
Length of CHD diagnosis (months) | 36.0 (1.0–360.0) |
CHD family history (n, %) | 55 (42.6) |
Diabetes | 57 (44.2) |
High cholesterol | 129 (100) |
Hypertension | 108 (83.7) |
Ex-smoker | 74 (57.4) |
Current smoker | 26 (20.2) |
Alcohol | 30 (23.3) |
PTCA/Stent therapy | 89 (69.0) |
CABG therapy | 31 (24.0) |
Medication | |
Antiplatelets | 123 (95.3) |
Nitrates | 34 (26.4) |
Beta-blockers | 89 (69.0) |
ACE inhibitors | 58 (45.0) |
Calcium antagonists | 28 (21.7) |
Lipid-lowering drugs | 122 (94.6) |
Others | 120 (93.0) |
Physiological data | |
Triglycerides (mmol/L) | 1.38 (0.52–16.01) |
Total cholesterol (mmol/L) | 4.06 (2.45–10.52) |
Low-density lipoprotein (mmol/L) | 2.18 (0.53–6.07) |
High-density lipoprotein (mmol/L) | 1.11 ± 0.24 |
Fasting blood glucose (mmol/L) | 5.75 (4.00–22.50) |
Systolic blood pressure (mmHg) | 135.90 ± 23.51 |
Diastolic blood pressure (mmHg) | 74.22 ± 11.41 |
BMI | 26.70 ± 5.04 |